Linked Life Data

20022918

Source:http://linkedlifedata.com/resource/pubmed/id/20022918

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20022918rdf:typepubmed:Citationlld:pubmed
pubmed-article:20022918lifeskim:mentionsumls-concept:C0014279lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C0384648lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C0206492lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C0963088lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C1825592lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C1705947lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:20022918lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:20022918pubmed:issue3lld:pubmed
pubmed-article:20022918pubmed:dateCreated2010-2-5lld:pubmed
pubmed-article:20022918pubmed:abstractTextBispecific antibodies (bsAbs) present an attractive opportunity to combine the additive and potentially synergistic effects exhibited by combinations of monoclonal antibodies (mAbs). Current challenges for engineering bsAbs include retention of the binding affinity of the parent mAb or antibody fragment, the ability to bind both targets simultaneously, and matching valency with biology. Other factors to consider include structural stability and expression of the recombinant molecule, both of which may have significant impact on its development as a therapeutic. Here, we incorporate selection of stable, potent single-chain variable fragments (scFvs) early in the engineering process to assemble bsAbs for therapeutic applications targeting the cytokines IL-17A/A and IL-23. Stable scFvs directed against human cytokines IL-23p19 and IL-17A/A were isolated from a human Fab phage display library via batch conversion of panning output from Fabs to scFvs. This strategy integrated a step for shuffling V regions during the conversion and permitted the rescue of scFv molecules in both the V(H)V(L) and the V(L)V(H) orientations. Stable scFvs were identified and assembled into several bispecific formats as fusions to the Fc domain of human IgG1. The engineered bsAbs are potent neutralizers of the biological activity of both cytokines (IC(50) < 1 nM), demonstrate the ability to bind both target ligands simultaneously and display stability and productivity advantageous for successful manufacture of a therapeutic molecule. Pharmacokinetic analysis of the bsAbs in mice revealed serum half-lives similar to human mAbs. Assembly of bispecific molecules using stable antibody fragments offers an alternative to reformatting mAbs and minimizes subsequent structure-related and manufacturing concerns.lld:pubmed
pubmed-article:20022918pubmed:languageenglld:pubmed
pubmed-article:20022918pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:citationSubsetIMlld:pubmed
pubmed-article:20022918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20022918pubmed:statusMEDLINElld:pubmed
pubmed-article:20022918pubmed:monthMarlld:pubmed
pubmed-article:20022918pubmed:issn1741-0134lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:PresnellScott...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:WestJamesJlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LevinSteven...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LewisPatsyPlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:BrenderTyTlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:McKernanPatri...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:SnavelyMarkMlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:GilbertsonDeb...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:OstranderCrai...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:MabryRobertRlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:ApplebyMark...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:ChungChanClld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:KuijperJoseph...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LockwoodLuann...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LewisKatherin...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:MooreMargaret...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LewisKenneth...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:FrankAmandaAlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:BukowskiThoma...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LumKarenKlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:OkadaShannonSlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:ReardonBrianBlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:LantryMeganMlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:Byrnes-BlakeK...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:MeengsBrentBlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:BrodyJennifer...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:BontadelliKri...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:ArdourelDanDlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:FrankeSecilSlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:VuTuyenTlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:WolfAnitraAlld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:HamacherNels...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:StevensBrenda...lld:pubmed
pubmed-article:20022918pubmed:authorpubmed-author:JulienSusan...lld:pubmed
pubmed-article:20022918pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20022918pubmed:volume23lld:pubmed
pubmed-article:20022918pubmed:ownerNLMlld:pubmed
pubmed-article:20022918pubmed:authorsCompleteYlld:pubmed
pubmed-article:20022918pubmed:pagination115-27lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:meshHeadingpubmed-meshheading:20022918...lld:pubmed
pubmed-article:20022918pubmed:year2010lld:pubmed
pubmed-article:20022918pubmed:articleTitleEngineering of stable bispecific antibodies targeting IL-17A and IL-23.lld:pubmed
pubmed-article:20022918pubmed:affiliationZymoGenetics, Inc., Seattle, WA 98102, USA. mabryr@zgi.comlld:pubmed
pubmed-article:20022918pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20022918pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20022918lld:pubmed